Gensight Biologics S.a annual ebitda margin
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a EBITDA Margin Growth & History (SIGHT)
Gensight Biologics S.a's ebitda margin was −868,800.00% for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −868,800.00% | −867816.40 pp |
| 2024 | 2024-12-31 | −983.60% | +1188.22 pp |
| 2023 | 2023-12-31 | −2,171.82% | −1134.88 pp |
| 2022 | 2022-12-31 | −1,036.95% | −521.44 pp |
| 2021 | 2021-12-31 | −515.50% | +30.88 pp |
| 2020 | 2020-12-31 | −546.38% | — |
Gensight Biologics S.a ebitda margin trends
Over the last five fiscal years, Gensight Biologics S.a's ebitda margin decreased from −546.38% to −868,800.00%, a change of −868253.62 percentage points.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...